Elixxer Stock Net Income
| ELIXF Stock | USD 0.03 0.00 0.00% |
As of the 5th of February, Elixxer shows the Mean Deviation of 26.62, standard deviation of 85.53, and Variance of 7315.82. Elixxer technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Elixxer coefficient of variation and maximum drawdown to decide if Elixxer is priced favorably, providing market reflects its regular price of 0.0335 per share. As Elixxer appears to be a penny stock we also advise to verify its jensen alpha numbers.
Elixxer's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Elixxer's valuation are provided below:Elixxer does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Elixxer |
Elixxer 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Elixxer's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Elixxer.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Elixxer on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Elixxer or generate 0.0% return on investment in Elixxer over 90 days. Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland More
Elixxer Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Elixxer's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Elixxer upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1187 | |||
| Maximum Drawdown | 719.3 | |||
| Value At Risk | (19.05) | |||
| Potential Upside | 13.85 |
Elixxer Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elixxer's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Elixxer's standard deviation. In reality, there are many statistical measures that can use Elixxer historical prices to predict the future Elixxer's volatility.| Risk Adjusted Performance | 0.0978 | |||
| Jensen Alpha | 11.61 | |||
| Total Risk Alpha | 3.87 | |||
| Treynor Ratio | (0.40) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Elixxer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Elixxer February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0978 | |||
| Market Risk Adjusted Performance | (0.39) | |||
| Mean Deviation | 26.62 | |||
| Coefficient Of Variation | 836.86 | |||
| Standard Deviation | 85.53 | |||
| Variance | 7315.82 | |||
| Information Ratio | 0.1187 | |||
| Jensen Alpha | 11.61 | |||
| Total Risk Alpha | 3.87 | |||
| Treynor Ratio | (0.40) | |||
| Maximum Drawdown | 719.3 | |||
| Value At Risk | (19.05) | |||
| Potential Upside | 13.85 | |||
| Skewness | 6.79 | |||
| Kurtosis | 50.41 |
Elixxer Backtested Returns
Elixxer is out of control given 3 months investment horizon. Elixxer secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We have analyzed and interpolated nineteen different technical indicators, which can help you to evaluate if expected returns of 11.27% are justified by taking the suggested risk. Use Elixxer Mean Deviation of 26.62, variance of 7315.82, and Standard Deviation of 85.53 to evaluate company specific risk that cannot be diversified away. Elixxer holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -25.7, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Elixxer are expected to decrease by larger amounts. On the other hand, during market turmoil, Elixxer is expected to outperform it. Use Elixxer coefficient of variation, total risk alpha, as well as the relationship between the Total Risk Alpha and rate of daily change , to analyze future returns on Elixxer.
Auto-correlation | -0.14 |
Insignificant reverse predictability
Elixxer has insignificant reverse predictability. Overlapping area represents the amount of predictability between Elixxer time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Elixxer price movement. The serial correlation of -0.14 indicates that less than 14.0% of current Elixxer price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.14 | |
| Spearman Rank Test | -0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Elixxer reported net income of (3.66 Million). This is 101.07% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.64% higher than that of the company.
Elixxer Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixxer's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Elixxer could also be used in its relative valuation, which is a method of valuing Elixxer by comparing valuation metrics of similar companies.Elixxer is currently under evaluation in net income category among its peers.
Elixxer Fundamentals
| Return On Equity | -3.41 | |||
| Return On Asset | -0.031 | |||
| Operating Margin | (8.81) % | |||
| Current Valuation | 9.36 M | |||
| Shares Outstanding | 11.35 M | |||
| Shares Owned By Insiders | 34.62 % | |||
| Shares Owned By Institutions | 32.04 % | |||
| Price To Book | 2.45 X | |||
| Price To Sales | 139.36 X | |||
| Gross Profit | 42.41 K | |||
| EBITDA | (1.94 M) | |||
| Net Income | (3.66 M) | |||
| Cash And Equivalents | 4.22 M | |||
| Cash Per Share | 0.37 X | |||
| Total Debt | 8.02 M | |||
| Debt To Equity | 1.60 % | |||
| Current Ratio | 0.65 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (4.02 M) | |||
| Earnings Per Share | (0.62) X | |||
| Beta | 1.34 | |||
| Market Capitalization | 10.14 M | |||
| Total Asset | 16.84 M | |||
| Z Score | 0.6 | |||
| Net Asset | 16.84 M |
About Elixxer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixxer's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixxer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixxer based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Elixxer Pink Sheet
Elixxer financial ratios help investors to determine whether Elixxer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixxer with respect to the benefits of owning Elixxer security.